Shreyaskumar Patel

794 total citations
20 papers, 583 citations indexed

About

Shreyaskumar Patel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Shreyaskumar Patel has authored 20 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Shreyaskumar Patel's work include Sarcoma Diagnosis and Treatment (13 papers), Vascular Tumors and Angiosarcomas (6 papers) and Cardiac tumors and thrombi (5 papers). Shreyaskumar Patel is often cited by papers focused on Sarcoma Diagnosis and Treatment (13 papers), Vascular Tumors and Angiosarcomas (6 papers) and Cardiac tumors and thrombi (5 papers). Shreyaskumar Patel collaborates with scholars based in United States, Italy and Belgium. Shreyaskumar Patel's co-authors include Vinod Ravi, Jennifer Cavalieri, Henry T. Lynch, Jane F. Lynch, Robert W. Beart, Robert S. Benjamin, Kelly K. Hunt, Barry W. Feig, Stephan A. Vorburger and Janice N. Cormier and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and Cancer.

In The Last Decade

Shreyaskumar Patel

19 papers receiving 567 citations

Peers

Shreyaskumar Patel
Eisuke Shiba Japan
Ravin Ratan United States
Evan Rosenbaum United States
Ghadah Al Sannaa United States
Veridiana Pires de Camargo Brazil
A. Brach del Prever Italy
Necati Alkış Türkiye
Teruto Isayama Japan
Marc Ladanyi United States
Thibaud Valentin France
Eisuke Shiba Japan
Shreyaskumar Patel
Citations per year, relative to Shreyaskumar Patel Shreyaskumar Patel (= 1×) peers Eisuke Shiba

Countries citing papers authored by Shreyaskumar Patel

Since Specialization
Citations

This map shows the geographic impact of Shreyaskumar Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shreyaskumar Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shreyaskumar Patel more than expected).

Fields of papers citing papers by Shreyaskumar Patel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shreyaskumar Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shreyaskumar Patel. The network helps show where Shreyaskumar Patel may publish in the future.

Co-authorship network of co-authors of Shreyaskumar Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Shreyaskumar Patel. A scholar is included among the top collaborators of Shreyaskumar Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shreyaskumar Patel. Shreyaskumar Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Banu, Matei A., et al.. (2024). The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol. Neurosurgical FOCUS. 56(5). E15–E15. 2 indexed citations
2.
Chiang, Yi‐Ju, Anthony P. Conley, Dejka M. Araujo, et al.. (2024). Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST).. Journal of Clinical Oncology. 42(16_suppl). 11583–11583. 1 indexed citations
3.
Movva, Sujana, Alexander I. Spira, Erika Hamilton, et al.. (2022). Surufatinib in U.S. patients with soft tissue sarcoma.. Journal of Clinical Oncology. 40(16_suppl). 11557–11557. 1 indexed citations
4.
5.
Gounder, Mrinal M., Gary K. Schwartz, Robin L. Jones, et al.. (2022). MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.. Journal of Clinical Oncology. 40(16_suppl). TPS11589–TPS11589. 4 indexed citations
6.
Kairemo, Kalevi, Elmer Santos, Homer A. Macapinlac, et al.. (2020). Molecular Imaging with 3′-deoxy-3′[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics. 10(3). 125–125. 5 indexed citations
7.
Somaiah, Neeta, Anthony P. Conley, Heather Lin, et al.. (2020). A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.. Journal of Clinical Oncology. 38(15_suppl). 11509–11509. 12 indexed citations
8.
Zheng, Jing, Anthony P. Conley, Ravin Ratan, et al.. (2020). Modulation of YAP/ TAZ by statins to improve survival in epithelioid hemangioendothelioma (EHE).. Journal of Clinical Oncology. 38(15_suppl). e23527–e23527. 4 indexed citations
9.
Parkes, Amanda, Shreyaskumar Patel, Cheuk Hong Leung, et al.. (2018). Systemic therapy regimen outcomes in metastatic phyllodes tumors of the breast.. Journal of Clinical Oncology. 36(15_suppl). 11554–11554. 1 indexed citations
10.
11.
Reddy, Neeti, Rohit Moudgil, Juan Lopez‐Mattei, et al.. (2017). Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Canadian Journal of Cardiology. 33(10). 1335.e13–1335.e15. 47 indexed citations
12.
Ravi, Vinod, Eric M. Sanford, Wei‐Lien Wang, et al.. (2016). Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. Journal of the National Comprehensive Cancer Network. 14(5). 499–502. 32 indexed citations
13.
Fu, Siqing, Jennifer J. Wheler, David S. Hong, et al.. (2016). Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.. Journal of Clinical Oncology. 34(15_suppl). 11057–11057. 3 indexed citations
14.
Subbiah, Vivek, Rishi Agarwal, Filip Jankú, et al.. (2014). Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine.. Journal of Clinical Oncology. 32(15_suppl). 10595–10595. 1 indexed citations
15.
Livingston, J. Andrew, Kenneth R. Hess, Aung Naing, et al.. (2014). Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience.. Journal of Clinical Oncology. 32(15_suppl). 10531–10531. 1 indexed citations
16.
Ravi, Vinod & Shreyaskumar Patel. (2013). Vascular Sarcomas. Current Oncology Reports. 15(4). 347–355. 38 indexed citations
17.
Vorburger, Stephan A., Yan Xing, Kelly K. Hunt, et al.. (2005). Angiosarcoma of the breast. Cancer. 104(12). 2682–2688. 153 indexed citations
18.
Jiménez, Camilo, Hyung-Woo Kim, Donald A. Berry, et al.. (2005). Primary Hyperparathyroidism and Osteosarcoma: Examination of a Large Cohort Identifies Three Cases of Fibroblastic Osteosarcoma. Journal of Bone and Mineral Research. 20(9). 1562–1568. 15 indexed citations
19.
Vadhan‐Raj, Saroj, Lesley Murray, Carlos Bueso-Ramos, et al.. (1997). Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer. Annals of Internal Medicine. 126(9). 673–681. 163 indexed citations
20.
Lynch, Henry T., et al.. (1994). Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Diseases of the Colon & Rectum. 37(3). 260–267. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eisuke Shiba Breakdown of academic impact, for papers by Ravin Ratan Breakdown of academic impact, for papers by Evan Rosenbaum Breakdown of academic impact, for papers by Ghadah Al Sannaa Breakdown of academic impact, for papers by Veridiana Pires de Camargo Breakdown of academic impact, for papers by A. Brach del Prever Breakdown of academic impact, for papers by Necati Alkış Breakdown of academic impact, for papers by Teruto Isayama Breakdown of academic impact, for papers by Marc Ladanyi Breakdown of academic impact, for papers by Thibaud Valentin
Rankless by CCL
2026